Medicine network - August 10, erythromycin eye ointment, compound liquorice tablets is a lot of families, a necessary medicine, mosquito bites, little ailments such as colds cough disaster can be used, the price of a few cents also left many good memories. These families common medicine recently began to rise in price, however, in some places, appear even doubling the rise in the price of cheap drugs, some drug prices 20 times within a year, even if such a medicine still is hard to find.
Such news has been repeated, and has sparked rounds of debate. Unfortunately, the seemingly lively public discussion has yet to form an effective solution. Then, every once in a while, the same phenomenon will be fired.
Similarly, the core message is nothing more than two points: a big increase in cheap medicine, while another part of cheap medicine is short or gone. For this, consumers have a lot of opinions, and the relevant drug companies are suffering... The price of family medicine has skyrocketed, and it is clearly a multi-party interest game saw.
To be sure, the price of the drug, which has been described as "heart-stopping", has skyrocketed, and a lot of it has gone from just a few cents to a few dollars, to a few dollars from a few dollars. Although the price is more than doubled, its "absolute value" is not high. Perhaps, this round of price boom, more or as drug pricing right after the opening of "catch-up", this is a return to the market pricing of logic, to find the equilibrium price.
Compared with the public's natural aversion to rising prices, drug companies may feel that the price of cheap medicine has risen too little and too slowly. According to some companies, even if nowadays based drug prices are at record highs, but still not reached the break-even line of its own - this assertion is not to believe, but which leads to some objective problems still have to face up to. The reality is that, with the high concentration of the upstream production elements, the monopoly situation is objectively formed, which directly leads to the rocketing of the original price rocket ship. In a sense, the downstream drug companies are suffering from the truth.
Based on today's market pattern, the so-called "cheap medicine" in the past is likely to be gone forever. It doesn't make sense to dwell on feelings and memories to remember the age when the family used to use the cabbage price. It is really worth thinking about how to establish a set of fair pricing rules in the new game mode. Today, the terminal sales of basic drugs fully realize the market price, while the upstream of its industrial chain is full of "monopoly pricing". Such an unbalanced distribution of interests will only lead to the excessive cost of most people and the excessive interest of the minority.
In order to curb the inflation of the price of the drug, finally we should get back to the source of the industrial chain. In this respect, it depends on the functional departments to continue to strengthen the anti-monopoly law enforcement in the pharmaceutical industry. On the other hand, we need to speed up the distribution process of relevant production licenses and sales licenses on the premise of strict requirements, and then support more targeted manufacturing enterprises. The obvious truth is that the only way to ensure the true fairness of terminal pricing is to achieve sufficient competition upstream. |
